3 ratings / 3.33 average

Pharmacotherapeutic Options for Pulmonary Arterial Hypertension

Myung H Park, MD

Pulmonary hypertension (PH) was first described by the German physician Ernst von Romberg as “sclerosis of the pulmonary arteries” in 1891, and was considered to be a uniformly fatal disease with an expected survival of <3 years [1,2]. However, an explosion of progress over the past 30 years has resulted in tremendous advances in the understanding of the pathobiology and mechanisms of this disease, through which have developed a systematic approach for diagnosis and eight approved therapies for pulmonary arterial hypertension (PAH). This review will focus on current concepts of mechanisms, diagnostic strategies, and treatment approaches for PAH.

Return to top


Congenital Heart Disease and Pulmonary Arterial Hypertension: Focus on Eisenmenger’s Syndrome
Julie Wacker and Maurice Beghetti, MD
CML Pulmonary Hypertension
Endothelial Progenitor Cells as a Target for Therapy of Pulmonary Hypertension
Laszlo Farkas, MD1,2,3, and Martin R Kolb, MD, PhD1,2
CML Pulmonary Hypertension
Inflammatory Mechanisms 
in Pulmonary Hypertension
Ali Sadoughi, MD1,2, Yinzhong Zhang MD, PhD1, Edmund J Miller, PhD, FRSC1,3,4, and Arunabh Talwar, MD, FCC P1,2,3,4
CML Pulmonary Hypertension
Noninvasive Imaging in the Evaluation 
of Pulmonary Hypertension
Asghar A Fakhri, MD1, Vikas K Rathi, MD, FACC2, Rachel Hughes-Doichev, MD, FASE1, and Raymond L Benza, MD1
CML Pulmonary Hypertension
Sickle Cell Disease-Associated Pulmonary Hypertension: the Effect of Anemia and High Cardiac Output
Shoaib Alam, MD, and Gregory J Kato, MD
CML Pulmonary Hypertension